<DrugInformationSummary id="CDR0000815281"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>Tislelizumab-jsgr works by keeping cancer cells from suppressing the immune system. It binds to the protein PD-1 on the surface of immune cells called T cells, allowing the immune system to recognize and kill the cancer cells. Tislelizumab-jsgr is a type of immunotherapy (immune checkpoint inhibitor) and a type of targeted therapy (monoclonal antibody).</DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/tislelizumab-jsgr">Tislelizumab-jsgr</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000770893">tislelizumab-jsgr</TerminologyLink><GlossaryLink ref="CDR0000815283">tislelizumab</GlossaryLink><USBrandNames><USBrandName>Tevimbra</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>TIS-leh-LIZ-yoo-mab</TermPronunciation><MediaLink ref="CDR0000815707" type="audio/mpeg" alt="" language="en" id="_3"/><MediaLink ref="CDR0000815708" type="audio/mpeg" alt="" language="es" id="_4"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08ef1e3e-496f-4b0b-94ee-fbba3cc1985a&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Tislelizumab-jsgr</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08ef1e3e-496f-4b0b-94ee-fbba3cc1985a&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_1"><Title>Use in Cancer</Title>                                                              
  <Para id="_2">Tislelizumab-jsgr
         is approved to treat adults with:</Para>                          
  <ItemizedList Style="bullet" id="_3">
   <ListItem><Strong><GlossaryTermRef href="CDR0000444989" dictionary="Cancer.gov" audience="Patient">Esophageal cancer</GlossaryTermRef></Strong> that cannot be removed by surgery or has spread to other parts of the body. It is used in patients with <GlossaryTermRef href="CDR0000046595" dictionary="Cancer.gov" audience="Patient">squamous cell carcinoma</GlossaryTermRef> of the esophagus. It is given:<ItemizedList Style="bullet" id="_5"><ListItem> with <GlossaryTermRef href="CDR0000045841" dictionary="Cancer.gov" audience="Patient">platinum</GlossaryTermRef>-based chemotherapy as the first treatment in patients whose cancer has the <GlossaryTermRef href="CDR0000797389" dictionary="Cancer.gov" audience="Patient">PD-L1</GlossaryTermRef> protein</ListItem><ListItem>alone in patients whose cancer was treated with <GlossaryTermRef href="CDR0000301626" dictionary="Cancer.gov" audience="Patient">systemic chemotherapy</GlossaryTermRef> that did not include a PD-L1 or <GlossaryTermRef href="CDR0000777027" dictionary="Cancer.gov" audience="Patient">PD-1</GlossaryTermRef>  inhibitor</ListItem></ItemizedList> </ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000454513" dictionary="Cancer.gov" audience="Patient">Gastric adenocarcinoma</GlossaryTermRef> </Strong> or <Strong><GlossaryTermRef href="CDR0000302458" dictionary="Cancer.gov" audience="Patient">gastroesophageal junction</GlossaryTermRef> <GlossaryTermRef href="CDR0000046216" dictionary="Cancer.gov" audience="Patient">adenocarcinoma</GlossaryTermRef></Strong> that has the PD-L1 protein, is <GlossaryTermRef href="CDR0000774531" dictionary="Cancer.gov" audience="Patient">HER2 negative</GlossaryTermRef>, and cannot be removed by surgery or has spread to other parts of the body. It is given with platinum-based chemotherapy and a <GlossaryTermRef href="CDR0000386207" dictionary="Cancer.gov" audience="Patient">fluoropyrimidine</GlossaryTermRef> as the first treatment.</ListItem>
   
   </ItemizedList>
  <Para id="_4">Tislelizumab-jsgr
         is also being studied in the treatment of other types of
         cancer.</Para>
 </Section><Section id="_About"><Title>More About Tislelizumab-jsgr</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/770893">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para>

<Para id="_About_8.27">MedlinePlus Information on <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a624026.html">Tislelizumab-jsgr</ExternalRef> - A lay language summary of important information about this drug that may include the following:</Para>
<ItemizedList Style="bullet" id="_About_9.28"><ListItem>warnings about this drug,</ListItem><ListItem>what this drug is used for and how it is used,</ListItem><ListItem>what you should tell your doctor before using this drug,</ListItem><ListItem>what you should know about this drug before using it, </ListItem><ListItem>other drugs that may interact with this drug, and</ListItem><ListItem>possible side effects.  </ListItem></ItemizedList><Para id="_About_10.29">Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.  This patient information sheet applies only to approved uses of the drug.  However, much of the information may also apply to unapproved uses that are being studied.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Therapy to Treat Cancer</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies">Monoclonal Antibodies</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C121775">Find Clinical Trials for Tislelizumab-jsgr</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2024-04-11</DateFirstPublished><DateLastModified>2025-03-07</DateLastModified></DrugInformationSummary>
